| pubmed-article:1600584 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1600584 | lifeskim:mentions | umls-concept:C0062527 | lld:lifeskim |
| pubmed-article:1600584 | lifeskim:mentions | umls-concept:C0008059 | lld:lifeskim |
| pubmed-article:1600584 | lifeskim:mentions | umls-concept:C0037173 | lld:lifeskim |
| pubmed-article:1600584 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
| pubmed-article:1600584 | lifeskim:mentions | umls-concept:C0301872 | lld:lifeskim |
| pubmed-article:1600584 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
| pubmed-article:1600584 | lifeskim:mentions | umls-concept:C0016441 | lld:lifeskim |
| pubmed-article:1600584 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:1600584 | pubmed:dateCreated | 1992-7-15 | lld:pubmed |
| pubmed-article:1600584 | pubmed:abstractText | The immunogenicity of four different dosages of yeast-derived hepatitis B vaccine (Merck, Sharp & Dohme: 0.6 micrograms, 1.25 micrograms, 2.5 micrograms and 5.0 micrograms), administered at 0, 1 and 6 months (0-1-6 schedule) intramuscularly, was evaluated in 122 seronegative healthy children 1-12 years of age. Three months after the first dose, 83.9-100% of the vaccinees seroconverted. Peak geometric mean titres (GMT) of between 1088 mlU/ml and 1699 mlU/ml were attained 3 months after completion of the vaccination schedule. After 24 months, anti-HBs (antibody to hepatitis B surface antigen) was detected in 93.1-100% of the vaccinees, but the GMT dropped to between 214.3 mlU/ml and 303.5 mlU/ml. After 48 months, 88.8-100% of the vaccinees continued to possess anti-HBs and 70.3-87% had titres above 10 mlU/ml. As expected, the GMT declined further to between 72.6 mlU/ml and 118.8 mlU/ml. There were no significant differences in seroconversion rates and GMT among the different dosage groups. All the vaccinees remained asymptomatic and free from hepatitis B virus infection. The study showed that reduced dosages of the vaccine (0.6 micrograms, 1.25 micrograms and 2.5 micrograms) were as immunogenic as the standard dose (5 micrograms); the 2.5-micrograms dose was recommended for the national childhood immunization programme in Singapore. No booster is necessary for at least four years after vaccination. | lld:pubmed |
| pubmed-article:1600584 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1600584 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1600584 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1600584 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1600584 | pubmed:issn | 0042-9686 | lld:pubmed |
| pubmed-article:1600584 | pubmed:author | pubmed-author:ChanS HSH | lld:pubmed |
| pubmed-article:1600584 | pubmed:author | pubmed-author:OonC JCJ | lld:pubmed |
| pubmed-article:1600584 | pubmed:author | pubmed-author:GohK TKT | lld:pubmed |
| pubmed-article:1600584 | pubmed:author | pubmed-author:TanK LKL | lld:pubmed |
| pubmed-article:1600584 | pubmed:author | pubmed-author:MARKM VMV | lld:pubmed |
| pubmed-article:1600584 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1600584 | pubmed:volume | 70 | lld:pubmed |
| pubmed-article:1600584 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1600584 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1600584 | pubmed:pagination | 233-9 | lld:pubmed |
| pubmed-article:1600584 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:1600584 | pubmed:meshHeading | pubmed-meshheading:1600584-... | lld:pubmed |
| pubmed-article:1600584 | pubmed:meshHeading | pubmed-meshheading:1600584-... | lld:pubmed |
| pubmed-article:1600584 | pubmed:meshHeading | pubmed-meshheading:1600584-... | lld:pubmed |
| pubmed-article:1600584 | pubmed:meshHeading | pubmed-meshheading:1600584-... | lld:pubmed |
| pubmed-article:1600584 | pubmed:meshHeading | pubmed-meshheading:1600584-... | lld:pubmed |
| pubmed-article:1600584 | pubmed:meshHeading | pubmed-meshheading:1600584-... | lld:pubmed |
| pubmed-article:1600584 | pubmed:meshHeading | pubmed-meshheading:1600584-... | lld:pubmed |
| pubmed-article:1600584 | pubmed:meshHeading | pubmed-meshheading:1600584-... | lld:pubmed |
| pubmed-article:1600584 | pubmed:meshHeading | pubmed-meshheading:1600584-... | lld:pubmed |
| pubmed-article:1600584 | pubmed:meshHeading | pubmed-meshheading:1600584-... | lld:pubmed |
| pubmed-article:1600584 | pubmed:meshHeading | pubmed-meshheading:1600584-... | lld:pubmed |
| pubmed-article:1600584 | pubmed:meshHeading | pubmed-meshheading:1600584-... | lld:pubmed |
| pubmed-article:1600584 | pubmed:meshHeading | pubmed-meshheading:1600584-... | lld:pubmed |
| pubmed-article:1600584 | pubmed:meshHeading | pubmed-meshheading:1600584-... | lld:pubmed |
| pubmed-article:1600584 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1600584 | pubmed:articleTitle | Comparison of the immune response of four different dosages of a yeast-recombinant hepatitis B vaccine in Singapore children: a four-year follow-up study. | lld:pubmed |
| pubmed-article:1600584 | pubmed:affiliation | Quarantine & Epidemiology Department, Ministry of the Environment, Singapore. | lld:pubmed |
| pubmed-article:1600584 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1600584 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:1600584 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:1600584 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1600584 | lld:pubmed |
